An interventional study of Transcranial direct current stimulation (tDCS) and Magnetic Resonance Imaging in First Episode Psychosis (FEP) and Psychosis, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Psychotic Disorders with a site in United Kingdom — 19 open to participants now, 22 under way, 4 of them phase 3. Psychotic Disorders · United Kingdom.
Among the 75 studies in Psychotic Disorders with a site in United Kingdom, this one is the 23rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 7 that started in 2026, is one of 37 with no phase, reaches primary completion later than 11 of the 21 other live ones, and was the 64th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →19 of the 75 studies in Psychotic Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom, Austria, Germany and 6 more countries
Ages 16–40
Lancashire and South Cumbria NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 55–90
University of Manchester · Sites in United Kingdom
Ages 16+
King's College London · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 12 · Phase 4 5
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 106 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 59 across the 60 interventional studies, 300 across the 15 observational. Of the 45 that completed or were terminated, 9 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 75 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 2 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Psychotic Disorders with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07252206University of ManchesterA Case Series of Culturally-adapted CBTp for Black People in the UK | 2026-12 |
| NCT07398365University of EdinburghMedical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients | 2026-12-31 |
| NCT06957808King's College LondonInvestigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia | 2027-01-20 |
| NCT03194815University of CambridgeIVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 | 2027-04-30 |
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 75 studies in Psychotic Disorders with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project aims to explore changes in brain chemistry in individuals who have recently experienced psychosis. Recent research suggests that chemicals in the brain, specifically one called glutamate, may behave differently in people who have experienced psychosis compared to those who have not. It is also known that some individuals with psychosis can find tasks involving memory and attention more challenging. This study aims at understanding how brain chemistry is linked to memory and attention, and if this is different between people who have and have not experienced psychosis.
The study will also investigate how a commonly used brain stimulation technique might help people with psychosis and other conditions by altering brain chemistry for a very short period. Non-invasive brain stimulation using very weak electrical stimulation has been used to help improve symptoms in individuals with psychosis and many other conditions, and has been shown to alter brain chemistry for a few hours after stimulation. However, it does not work for everyone. It will be investigated if levels of glutamate can predict whether brain stimulation will help an individual or not. In other words, the study investigates if glutamate can be used as a marker for tailoring treatments.
This project also aims to collect personal experiences or challenges that individuals with psychosis face. This information will be gathered through interviews. This will help to understand what specific difficulties individuals have, such as with certain aspects of memory and attention. The interview will also gather opinions and concerns about brain imaging and brain stimulation and current understandings of chemicals in the brain. For example, the study will explore why individuals may not want to take part in brain imaging or brain stimulation.
TRIAL / STUDY BACKGROUND INFORMATION AND RATIONALE
Cognitive impairment in psychosis:
Cognitive impairments occur in up to 80% of people living with psychosis. The recent landscape report, commissioned by the Wellcome Trust, highlighted that cognitive impairments are an "area of concern for people with psychosis" (p.36) and, furthermore, that "personalising the intervention approach...is desirable" (p.39). Specific cognitive symptoms are variable across individuals, but they are relevant for the individual as they predict day-to-day functioning and quality of life. Current interventions aiming at cognitive improvements are effective for some, but not all, individuals with psychosis. To increase the amount of viable and effective treatment options, a personalised approach based on improved understanding into the variability in cognitive impairments in psychosis is needed.
This project aims to explore perceptions of cognitive impairment \& treatment from those with first-hand experience (Study 2); to explore a potential neurochemical marker (glutamate levels, in particular) for cognitive functioning with a focus on working memory (WM) (Study 1a); and to assess how this marker may predict changes in response to a single 'accelerated' session of non-invasive brain stimulation using transcranial direct current stimulation (tDCS) (Study 1a). Additionally, the study aims to explore the effects of accelerated tDCS on neurochemistry in individuals with first-episode psychosis (FEP; Study 1b). This 'accelerated' approach involves applying two stimulations in proximity during one testing session as recommended by several authors to safely maximise potential stimulation effects. The investigators chose tDCS as intervention method due to its potential for influencing glutamate levels (see below). Through these three interconnected studies using functional magnetic resonance spectroscopy (fMRS), transcranial direct current stimulation (tDCS) and interview approaches, the study aims at better understanding and informing potential future treatment options for cognitive impairment in psychosis.
It is important to note that while this study will use tDCS as part of this project, this is not an interventional study, in the respect that it is not assessing the impact of tDCS directly on symptoms or quality of life. In study 1a, the investigators will explore statistical relationships between changes in neurochemistry during the cognitive task, and changes in task performance during and following tDCS. In study 1b, the study will explore how neurochemistry is temporarily altered following accelerated tDCS in a subset of FEP participants. This will allow to validate previous work in healthy controls showing changes in Glu following tDCS, and to assess relationships between task performance and neurometabolite change. Thus, study 1a aims at establishing a link between neurochemical changes and subsequent responses to tDCS, while study 1b, aims to corroborate that tDCS has indeed influenced neurochemical changes in FEP individuals. Further details in the sections below.
Experience of cognitive impairment and perceptions of interventions in psychosis:
There is relatively little research exploring the subjective impact of cognitive impairments experienced through psychosis. Yet, impairments in cognitive functioning are experienced by 75-80% of people living with psychosis, and any future intervention that is designed to alleviate these impairments will have to target the most salient concerns of individuals with lived experiences to enhance uptake and engagement with the intervention. Past research that has interviewed individuals with psychosis has found impairments in cognitive functioning negatively impact on individuals daily functioning, including vocational performance, and on their self-concept, and relationships with others. Further interviews have shown that the notion of future interventions designed to enhance cognitive strengths has been received positively by individuals with psychosis. However, except for these studies little is known about this area, and these studies focused on young people (aged 18-26) receiving treatment in Australia. Additionally, relatively little is known about the perceptions of this demographic about views towards non-invasive brain stimulation approaches and use of magnetic resonance imaging in potential treatment plans. Study 2 will use semi-structured interviews to improve insights into the subjective impact of cognitive impairment and perceptions of non-invasive brain stimulation/ imaging among NHS patients in the UK. These will give valuable insights into what matters to patients and how potential interventions are perceived.
Working memory (WM) and psychosis:
Although several different cognitive functions can be affected in individuals with psychosis (perceptions of which will be explored in study 2), some cognitive domains seem particularly vulnerable, including associative processes in episodic and working memory (WM). WM is a crucial component of goal-directed behaviour. For instance, in a conversation we need to keep our semantic goals (the main message we want to convey) active in WM as well as a representation of what has been said already. Similarly, if we want to evaluate whether our actions have been successful and in line with our goals, i.e. monitoring our own performance, we need to keep a representation of the context and relevant information active in WM. These monitoring processes are often compromised in individuals with schizophrenia, thereby impacting goal-directed behaviour. Thus, impairments in WM are linked to impairments in goal-directed behaviour and will impact on a range of everyday life tasks.
Evidence from brain imaging studies using magnetic resonance spectroscopy (MRS) have given recent insights into the neurochemistry which underlies our ability to perform WM tasks and potential differences between those with and without psychosis. MRS is a specialised form of magnetic resonance imaging (MRI) which allows for quantification of neuro-metabolites, including glutamate (Glu) and GABA, which play a key role in regulating activity within the brain. Recent work has revealed a link between cognitive functions in schizophrenia and MRS measures of glutamate acquired at rest. In more dynamic measures taken during a cognitive task using fMRS, Jelen et al (2019) found that levels of Glu increase when transitioning from low to high WM conditions in healthy controls but not in individuals with psychosis. In Study 1a, we will build on the previous literature by using fMRS to explore how neurometabolites, including Glu, vary during a WM task between individuals with first episode psychosis and controls and how these modulations in task-dependent Glu-level modulations are related to the individual's WM performance.
Modulating glutamate using tDCS:
There is some evidence that Glu levels in the brain may be related to treatment outcome. A recent meta-analysis showed increased medial frontal Glu levels in treatment-resistant psychosis but decreased Glu levels in treatment responders, indicating a preliminary association between Glu levels and treatment outcome. Therefore, it seems to be promising to further investigate the relationship between Glu levels, cognitive functions, and treatment outcomes.
After establishing how Glu changes in response to a WM task in both first episode psychosis (FEP) individuals and health controls, the study aims to evaluate if this natural flexibility in Glu is related to changes in Glu driven by external means which could be developed into robust therapies in the future. Specifically, Study 1a will explore the potential relationship between Glu change during the WM task and behavioural change attributed to transcranial direct current stimulation (tDCS). The investigators will then extend this in Study 1b to corroborate if Glu levels have indeed been modulated by exposure to tDCS.
Transcranial direct-current stimulation (tDCS) is a non-invasive brain stimulation method which can modulate Glu levels in stimulated brain areas. A weak current is applied to the scalp influencing the underlying cortex by altering the membrane potential of neurons proximal to the surface electrode. Anodal stimulation is frequently reported to increase the cortical excitability which can induce increased neural plasticity and thereby lead to functional changes that last longer than the actual stimulation. TDCS has the advantage that it can modulate Glu levels in targeted brain areas and, compared to many pharmacological interventions, has relatively mild and short-lasting side effects (e.g. tingling sensations), has demonstrated good tolerability within the majority of patient groups and has the potential to develop for home use in the future.
TDCS has already been used in individuals with schizophrenia to improve executive functions and learning as well as working memory and clinical symptoms. Although the effect sizes of tDCS stimulations are often noted to be variable within healthy individuals, studies in several different brain regions have shown links between relevant task performance and tDCS response.
The investigators propose that task-related Glu changes (measured with fMRS) predict more precisely who will benefit most from tDCS stimulation. The investigators will assess this in Study 1a through evaluating the relationship between fMRS measured Glu change during a WM task and performance change in the same take following tDCS. In a subset of participants (Study 1b), the study will additionally explore any change in fMRS measured Glu immediately following tDCS. Thus, the study will investigate the relationship between pre- and post-tDCS Glu modulations, within-task Glu modulations and behavioural task performance.
The aim in Study 1b is not to evaluate the effectiveness of tDCS (this would need to be tested in a follow-up RCT), but to establish the relationship between Glu dynamics in a cognitive task and the effect of an intervention that modulates the Glu system. The study involves a CE marked device which has been used extensively for research purposes.
The investigators do not anticipate that any of our results will affect future clinical practice directly, however, the information gathered form the various sub-studies will provide valuable knowledge that could provide the foundation for future intervention developments.
Inclusion Criteria for FEP Group (studies 1a and 1b):
Eligibility criteria for first episode psychosis group are as follows:
Exclusion Criteria for FEP Group (Studies 1a and 1b):
Inclusion Criteria for Healthy Matched Controls (Studies 1a and 1b):
Matched healthy control participants will be recruited from a local database of volunteers, from posters and online advertisements.
Inclusion criteria (matched controls):
Exclusion criteria for Health Matched Controls (Studies 1a and 1b):
Inclusion Criteria for participants with lived experiences of psychosis (Study 2):
Exclusion Criteria for participants with lived experiences of psychosis (Study 2):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study 1a: Will typically take place over 2-3 sessions (depending on participant's availability) spaced 1-7 days apart on average, and a 2-month follow up (FEP participants only). The first session (which could be split into two) will take approximately 4-5 hours in total consisting of several questionnaires, tasks, and up to 1 hour of MRI scanning. The second session will take approximately 2 hours and involve receiving tDCS stimulation and completing the cognitive task. The 2-month follow up will take up to 2 hours and involve assessing WM performance, symptoms scores (PANSS), CAPE-P15, quality of life and social and occupational functioning. Study 1b: Will take place on the same day as the second part of study 1a and will involve one additional scan of up to an hour in duration.
Device: Transcranial direct current stimulation (tDCS) · Diagnostic Test: Magnetic Resonance Imaging
2mA anodal stimulation to be delivered for 20 minutes using a Neuroconn DC stimulator PLUS which will be repeated once after a 20-minute break.
Using a 7T Philips scanner with total scanning session lasting no more than 1 hour.
Measures of glutamate and GABA change (quantified using fMRS) during a working memory task
Difference in glutamate and GABA levels between different phases/WM load in a working memory task (Study 1a).
Time frame: Day 1, during fMRS scan, blocks with working memory task vs. blocks with control task.
Correlation between glutamate and GABA responses during a WM task and tDCS outcome (accuracy)
Neurometabolite changes during a WM task (as described above, outcome measure 1) will be correlated with changes in accuracy in a WM task after tDCS brain stimulation.
Time frame: within 1 week
Correlation between glutamate and GABA responses during a WM task and tDCS outcome (reaction time)
Neurometabolite changes during a WM task (as described above, outcome measure 1) will be correlated with changes in reaction times in a WM task after tDCS brain stimulation.
Time frame: within 1 week
Qualitative data analysis: Perceived cognitive impairments in psychosis
Thematic analysis of impact of experiencing cognitive impairments (or perceived improvements) on individuals' lives in semi-structured interviews (Study 2).
Time frame: Study day 2
Qualitative data analysis: Expectations and concerns around interventions that involve brain scanning and brain stimulation
Themes (as outcome of a thematic analysis) that describe FEP participants' interests and expectations for future interventions designed to alleviate the impact of cognitive impairments, particularly regarding any future interventions using non-invasive brain stimulation methods (Study 2). Data will be collected in a semi-structured interview.
Time frame: Study day 2
Difference in glutamate levels during working memory task pre- and post-tDCS stimulation
Glutamate concentration in the medial frontal cortex while the participant is engaged in an associative working memory task pre-tDCS stimulation vs. post-tDCS stimulation
Time frame: within 1 week (pre- and post-tDCS fMRS acquisitions; post-tDCS scan will take place immediately after tDCS stimulation)
Difference in GABA levels during working memory task pre- and post-tDCS stimulation
GABA concentration in the medial frontal cortex while the participant is engaged in an associative working memory task pre-tDCS stimulation vs. post-tDCS stimulation
Time frame: within 1 week (pre- and post-tDCS fMRS acquisitions; post-tDCS scan will take place immediately after tDCS stimulation)
Changes in other neurometabolites (tCR, GSH) during different phases of a working memory task.
Level of neurometabolite concentration (tCR, GSH) in the medial frontal cortex during the associative Working Memeory task as compared to a control condition without working memory load in individuals with psychosis and matched controls.
Time frame: Day 1, during fMRS scan, blocks with working memory task vs. blocks with control task.
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and psychosis symptom severity (PANSS).
Neurometabolite concentration changes during an associative WM task will be correlated with symptom scores from PANSS.
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and psychosis symptom severity (SPS).
Neurometabolite concentration changes during an associative WM task will be correlated with symptom scores from Scale of Prodromal Symptoms (SPS).
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and psychosis symptom severity (CAPE-P15).
Neurometabolite concentration changes during an associative WM task will be correlated with symptom scores from the Community Assessment of Psychic Experiences (CAPE-P15).
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and socio-occupational performance (PSP).
Neurometabolite concentration changes during an associative WM task will be correlated with scores from the Personal and Social Performance Scale (PSP).
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and quality of life (WHOQOL-BREF).
Neurometabolite concentration changes during an associative WM task will be correlated with quality of life scores from the World Health Organisation Quality of Life Brief Version (WHOQOL-BREF).
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and experience of disability (WHODAS 2.0)
Neurometabolite concentration changes during an associative WM task will be correlated with disability assessment scores from the World Health Organisation Disability Assessment Schedule (WHODAS 2.0).
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task and autism spectrum symptoms (AQ-50).
Neurometabolite concentration changes during an associative WM task will be correlated with scores from the Autism Quotient - 50 item questionnaire.
Time frame: Within 2 months from first fMRS acquisition
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and accuracy in a change detection working memory task.
Neurometabolite concentration levels at rest (static MRS) will be correlated with accuracy (percentage of correct answers) in a change detection working memory task.
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and performance in the forward/backward number span task.
Neurometabolite concentration levels at rest (static MRS) will be correlated with the individual's number span (maximum number of numbers correctly recalled).
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and performance in the Corsi block test.
Neurometabolite concentration levels at rest (static MRS) will be correlated with the individual's block span (maximum number of blocks correctly recalled).
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and processing speed.
Neurometabolite concentration levels at rest (static MRS) will be correlated with processing speed as measured in the digit-symbol substitution test (number of correctly associated items in a fixed amount of time).
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and processing speed (simple and choice reaction time).
Neurometabolite concentration levels at rest (static MRS) will be correlated with processing speed as measured with a simple and a choice reaction time (RT) task (RT in simple RT task, difference in RT between choice RT task and simple RT task).
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and processing speed/attentional shifting (Trail Making Test).
Neurometabolite concentration levels at rest (static MRS) will be correlated with processing speed/attentional shifting performance as measured with the Trail Making Test (TMT, completion time).
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and cognitive control (interference).
Neurometabolite concentration levels at rest (static MRS) will be correlated with interference reaction times (difference between incongruent and congruent trial reaction times) in a cognitive control task.
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and performance monitoring.
Neurometabolite concentration levels at rest (static MRS) will be correlated with the error rate in a cognitive control task.
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration levels (glutamate, GABA) during rest (static MRS) and meta-cognitive monitoring.
Neurometabolite concentration levels at rest (static MRS) will be correlated with the percentage of perceived errors (relative to unperceived errors) in an error awareness task.
Time frame: Within 2 months of MRS data acquisition.
Correlation between WM performance and visual imagery scores (VVIQ)
Correlation between accuracy in the associative visual WM task and visual imagery scores as measured with the Vividness of Visual Imagery Questionnaire (VVIQ).
Time frame: WM performance and VVIQ will be acquired within 10 days.
Correlation between WM performance and visual imagery scores (SUIS)
Correlation between accuracy in the associative visual WM task and visual imagery scores as measured with the Spontaneous Use of Imagery Scale (SUIS).
Time frame: WM performance and SUIS will be acquired within 10 days.
Alignment between objective cognitive measures and subjective experiences of cognitive impairments
Qualitative data analysis: the self-reported cognitive strengths and deficits in Study 2 will be compared to the cognitive performance profile (accuracy, RTs, completion times) in working memory, attentional and cognitive control tasks from Study 1. This will be done on an individual case basis.
Time frame: Study day 2
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task (fMRS) and accuracy in a change detection working memory task.
Neurometabolite concentration during the associative working memory task (fMRS, percent change in neurometabolite level between WM task and control condition) will be correlated with accuracy (percentage of correct answers) in a change detection working memory task.
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task (fMRS) and processing speed (digit-symbol substitution task).
Neurometabolite concentration during the associative working memory task (fMRS, percent change in neurometabolite level between WM task and control condition) will be correlated with number of correctly associated items in the digit-symbol substitution task.
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task (fMRS) and processing speed (simple and choice RT).
Neurometabolite concentration during the associative working memory task (fMRS, percent change in neurometabolite level between WM task and control condition) will be correlated with reaction times in a simple RT task and the difference in reaction times between a simple and a choice RT task.
Time frame: Within 2 months of MRS data acquisition.
Correlation of neurometabolite concentration changes (glutamate, GABA) during WM task (fMRS) and processing speed/attentional shifting (Trail Making Test).
Neurometabolite concentration during the associative working memory task (fMRS, percent change in neurometabolite level between WM task and control condition) will be correlated with the completion times in the Trail Making Test.
Time frame: Within 2 months of MRS data acquisition.
Plan to share: Yes — Magnetic resonance spectroscopy (MRS/fMRS) data functional MRI data Performance on cognitive assessments at different study time points QoL and other questionnaire data interview transcripts or summarised interview data (depending on participant consent)
Time frame: Data will be shared after publication of the study results. Data shared in OSF and UK Data Service do not have a time limitation.
Access criteria: IPD from study 1a and b will be uploaded to OSF. Interview data will be deposited with the UK data service.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 18 months is below that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.